CRISPR-Based Genome Editing Approaches in Cancer Therapy
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell and Gene Therapy".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 189
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue explores the role of CRISPR-based genome editing approaches in cancer therapy. Genome editing using RNA-guided programmable clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) nucleases has revolutionized genetic research, offering unparalleled speed, efficiency, and precision. Since its first application in mammalian cells more than a decade ago, the CRISPR toolbox has rapidly expanded, continuously offering novel genetic tools aiding disease modeling and therapeutic approaches, including in cancer.
For this Special Issue, we welcome submissions that harness novel advancements of CRISPR-technology aimed at improving cancer treatments, including but not limited to CRISPR-based genome editing in cancer cells, immunotherapy approaches using CRISPR technology, CRISPR diagnostics for early cancer detection and monitoring, or the use of functional genomic screens to identify novel cancer-driving genes. Studies highlighting the role of using CRISPR-based genome editing for anti-cancer treatments are of particular interest.
By highlighting innovative research and translational applications, we endeavor to advance our understanding of how CRISPR-based genome editing approaches can shape personalized anti-cancer treatments.
Dr. Martin Pal
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CRISPR
- genome editing
- cancer therapy
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
